PJ

Paras Jain

Active Director Director DIN 10612237
DIN 10612237 First appointment May 2024
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value •••• Premium profile

About Paras Jain

Data last updated:

Paras Jain is a Director at Austim Pharma Private Limited (since 2024). Austim Pharma Private Limited reported revenue of ₹34,460 (FY 2025).

DIN 10612237
Primary Designation Director
First Appointment 25 May 2024
Oldest Company Age 3 yrs
Largest company Austim Pharma Private Limited · ₹34,460 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Austim Pharma Private Limited U46596AS2023PTC024899
Director25 May 20242023₹34,460 (FY 2025)Active

Board colleagues of Paras Jain

NameDINCompanyDesignation
Kavita Jain10241753Austim Pharma Private LimitedDirector
Prakash Basumatary08666883Austim Pharma Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Austim Pharma Private Limited
Premium access

Shareholding and investment profile for Paras Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Paras Jain

Paras Jain currently holds 1 directorship: Austim Pharma Private Limited (Director, since 25 May 2024, revenue ₹34,460 (FY 2025)).

Paras Jain was first appointed on 25 May 2024 as Director at Austim Pharma Private Limited.

The current boards of Paras Jain's companies include Kavita Jain (Austim Pharma Private Limited), Prakash Basumatary (Austim Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available